Pharming Group N.V. - ADR
PHAR
Get informed when a big investor buys or sells
+ FollowMarket Cap$782.1M
Close$
$15.60
61.8% upside
Current Fair Value
61.8% upsideUndervalued by 61.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $782.10 Million |
|---|---|
| Enterprise Value | $737.11 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.04 |
| Beta | 0.09 |
| Outstanding Shares | 70,140,400 |
Return
| Return on Equity | 3.13% |
|---|---|
| Return on Assets | 1.81% |
| Return on Invested Capital | 1662.21% |
Valuation & Multiples
| P/E Ratio | 66.79 |
|---|---|
| PEG | -103.02 |
| Price to Sales | 1.93 |
| Price to Book Ratio | 3.21 |
| Enterprise Value to Revenue | 2.1 |
| Enterprise Value to EBIT | 0.12 |
| Enterprise Value to Net Income | 87 |
| Total Debt to Enterprise | 0.15 |
| Debt to Equity | 0.42 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 30, 2026
EPS Estimate
$0.06
Average shareholder expectationRevenue Estimate
$99.52 M
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$0.12
Average shareholder expectationRevenue Estimate
$103.54 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 3.20%▲ 3.08% |
|---|---|
| Total Invested | $4.27M▲ 198.91% |
| Investors Holding | 18▲ 5.00% |
ESG Score
No data
About Pharming Group N.V.
407 employees
CEO: Sijmen de Vries Based in Leiden, the Netherlands, Pharming Group N.V. operates as a biopharmaceutical firm dedicated to advancing and marketing protein replacement therapies and precise medical solutions. Its global efforts, spanning the United States, ...